Edition:
United States

C R Bard Inc (BCR.N)

BCR.N on New York Stock Exchange

336.66USD
21 Nov 2017
Change (% chg)

$3.37 (+1.01%)
Prev Close
$333.29
Open
$334.10
Day's High
$336.98
Day's Low
$334.10
Volume
94,439
Avg. Vol
134,335
52-wk High
$336.98
52-wk Low
$206.28

Chart for

About

C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended... (more)

Overall

Beta: 0.53
Market Cap(Mil.): $24,294.30
Shares Outstanding(Mil.): 72.89
Dividend: 0.26
Yield (%): 0.31

Financials

  Industry Sector
P/E (TTM): -- 51.53 15.49
EPS (TTM): -- -- --
ROI: -- 13.47 11.95
ROE: -- 19.97 15.94

BRIEF-BD announces extension of exchange offers and consent solicitations for C. R. Bard, Inc.

* BD announces extension of exchange offers and consent solicitations for C. R. Bard, Inc. Notes Source text for Eikon: Further company coverage:

Oct 26 2017

BRIEF-C R Bard reports Q3 earnings per share $1.25

* Q3 earnings per share view $2.95 -- Thomson Reuters I/B/E/S

Oct 25 2017

Becton Dickinson wins conditional EU approval for $24 billion Bard buy

BRUSSELS U.S. medical equipment supplier Becton Dickinson secured EU antitrust approval for its $24-billion acquisition of U.S. peer C R Bard after it agreed to sell two businesses to allay competition concerns.

Oct 18 2017

Becton Dickinson wins conditional EU approval for $24 bln Bard buy

BRUSSELS, Oct 18 U.S. medical equipment supplier Becton Dickinson secured EU antitrust approval for its $24-billion acquisition of U.S. peer C R Bard after it agreed to sell two businesses to allay competition concerns.

Oct 18 2017

BRIEF-BD extends exchange offers and consent solicitations for C R Bard Inc notes

* BD announces extension of exchange offers and consent solicitations for C R Bard Inc notes

Sep 27 2017

BRIEF-BD announces extension of exchange offers and consent solicitations for C. R. Bard Inc notes

* BD announces extension of exchange offers and consent solicitations for C. R. Bard Inc notes

Aug 29 2017

BRIEF-C. R. Bard receives FDA premarket approval of the Lutonix

* C. R. Bard receives fda premarket approval of the lutonix® 035 drug coated balloon as the first and only DCB for the treatment of patients with dysfunctional av fistulae

Aug 28 2017

BRIEF-C.R. Bard shareholders approve proposed merger with Becton Dickinson

* Bard shareholders approve proposed merger with becton, dickinson

Aug 08 2017

BRIEF-Becton Dickinson extends exchange for C. R. Bard, Inc. notes

* BD announces extension of exchange offers and consent solicitations for C. R. Bard, Inc. Notes

Aug 01 2017

BRIEF-C R Bard receives civil investigative demand by DOJ in July

* Says in July, separate civil investigative demand was served to company by DOJ

Jul 28 2017

Earnings vs. Estimates